RICARDO-UK-LTD
30.3.2021 01:03:06 CEST | Business Wire | Press release
Cranfield Aerospace Solutions (CAeS) - the UK SME leading the Project Fresson consortium - announces it will exploit recent advances in hydrogen fuel cell technology to develop a commercially viable, retrofit powertrain solution for the nine-passenger Britten-Norman Islander aircraft.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210329005667/en/
Following a rigorous assessment of hydrogen technology innovators, CAeS is delighted to welcome Ricardo UK Ltd and Innovatus Technologies Ltd to the Fresson consortium. Ricardo UK Ltd brings expertise in fuel cell system development and Innovatus Technologies Ltd brings their innovative Scottish Hydrogen Fuel Tank (SHyFT) technology.
Steve Dyke, Managing Director Ricardo Automotive and Industrial EMEA Division said: “We are proud to join the Cranfield Aerospace Solutions consortium to play our part in helping to reduce the carbon footprint for commercial air passengers. We are already working on hydrogen and fuel cell technology, providing clean efficient solutions which reduce carbon and noxious emissions across a wide range of sectors. Our work for the Fresson consortium will enable us to consolidate and grow our hydrogen fuel cell and propulsion capability, so that Ricardo can achieve its ambition of becoming a world-leader in hydrogen and fuel cell services and solutions and help accelerate net zero transportation.”
Innovatus Technologies Ltd leads the field in next generation ultralightweight hydrogen tank design exploiting patented cellular core composite techniques. This is critical to the successful integration and exploitation of hydrogen fuel cell power systems in applications across aerospace, automotive, industrial, and marine sectors.
Ruan Swart, Chief Executive Officer Innovatus Technologies Ltd said: ““We are proud in being selected to join the Cranfield Aerospace Solutions, ‘Project Fresson’, consortium. Our unique and innovative SHyFT solution is game-changing in bringing zero carbon fuel cell energy to commercial reality in the transport sector. Project Fresson showcases important Scottish innovation and next generation hydrogen tank manufacturing in the UK.”
Project Fresson will deliver an emissions-free (zero CO2 ), hydrogen-fuel-cell-powered flying demonstrator by September 2022. Having completed a comprehensive evaluation of technologies and configurations for sustainable aircraft propulsion, the Fresson team concluded that hydrogen fuel cell technology is the optimum solution to meet environmental, regulatory and operational requirements for this size of aircraft, enabling zero carbon emissions and reducing operating costs. This has presented the Fresson consortium, which includes Britten-Norman and Cranfield University, with an opportunity to deliver an enhanced technology programme that surpasses the original demonstrator concept.
Paul Hutton, Chief Executive Officer, Cranfield Aerospace Solutions said: “This is incredibly important for the Project Fresson Team but also for everyone else around the world interested in zero emissions flight. This project can deliver the world’s first truly “green” passenger carrying airline services. The whole team is proud of what Project Fresson has achieved so far and excited about what is to come. I am very thankful for the support of the ATI and our investors for making this ground-breaking work a reality.”
Jenny Kavanagh, Chief Strategy Officer, Cranfield Aerospace Solutions added: “Covid-19 has caused the biggest crisis in aviation’s history. It’s important that, as the sector builds back better, it does so with sustainability at its heart. Project Fresson is more than just a technology demonstrator; it has one focus above all others: real operational and commercial viability.”
Project Fresson is supported by the ATI Programme, a joint Government and industry investment to maintain and grow the UK’s competitive position in civil aerospace design and manufacture. The programme, delivered through a partnership between the Aerospace Technology Institute (ATI), Department for Business, Energy & Industrial Strategy (BEIS) and Innovate UK, addresses technology, capability and supply chain challenges.
As a result of these changes, there is now no longer a need for the Rolls-Royce element of the aircraft programme. It is therefore Rolls-Royce’s intention to withdraw from Project Fresson and the consortium is going through the necessary steps for this to happen. We thank Rolls-Royce for its contribution to Project Fresson and wish its team well. Rolls-Royce will continue to actively research the use of hydrogen in aviation and this decision in no way reflects its overall view of hydrogen as a potential technology.
Ends
Notes to editors
- To follow the progress of Project Fresson, visit the microsite: www.projectfresson.uk or follow on Twitter @projectfresson.
- Cranfield Aerospace Solutions (CAeS) is an aerospace market leader in rapid prototyping of new aerospace concepts, modifications to existing aerospace platforms and integration of cutting-edge technologies to meet the most challenging issues facing the industry today. CAeS is the wholly owned commercial arm of Cranfield University. Visit: www.cranfieldaerospace.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210329005667/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom